BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06828055 (VK2735 in obesity without type 2 diabetes): BVCT ex-ante prediction vs. reported outcome

On 8 May 2025, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 26 Aug 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (strongly superior efficacy compared with both orforglipron and tirzepatide and non-inferior tolerability compared with orforglipron).

Clinical Trial

NCTID
NCT06828055
Acronym
VENTURE
Drug Name
VK2735
Drug MoA
oral GLP1R/GIPR dual agonist
Drug Modality
peptide
Drug Class
Best-In-Class
Therapeutic Area
Nutritional and Metabolic Diseases
Indication
obesity without type 2 diabetes
Human Patients
280
Sponsor
Viking Therapeutics
Phase
Phase 2

Prediction of , index 2015

Prospective Prediction
Prediction Index
2015
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit in weight reduction non-superior-non-inferior to retatrutide; moderately superior to tirzepatide; and strongly superior to orforglipron/GSBR1290/cagrisema)
Technical Prediction
SUCCESS (statistically significant clinical benefit in weight reduction compared with placebo with superior-to-tirzepatide tolerability)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
110 days in advance
Readout Data Interpretation
VK2735 oral 90mg achieved 9.8% placebo-adjusted weight reduction and 7% placebo-adjusted discontinuation rate at week 13; superior to 5.5% placebo-adjusted weight reduction at week 13 and superior to 7.7% placebo-adjusted discontinuation rate at week 72 achieved by orforglipron 36mg (see add'l link below); superior to 6.2% placebo-adjusted weight reduction at week 13 yet inferior to 3.6% placebo-adjusted discontinuation rate at week 72 achieved by tirzepatide 15mg (10.1056/NEJMoa2206038)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (strongly superior efficacy compared with both orforglipron and tirzepatide and non-inferior tolerability compared with orforglipron)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Dose Finding Study of VK2735 Oral Formulation for Weight Management in Subjects Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition
Phase
Phase 2
Status
Completed
Enrollment
280
Lead sponsor
Viking Therapeutics, Inc.
Conditions
Weight Loss
Interventions
DRUG: Placebo; DRUG: VK2735
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2024-12-18
Primary completion
2025-06-24
Completion
2025-08-15
Primary outcomes
  • Percent (relative) change from baseline in body weight after 13 weeks of treatment (13 Weeks)

NCT06828055 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials